

# EXECUTIVE SUMMARY

First Half 2024




## Main figures €Mn

|                     |                    |                    |
|---------------------|--------------------|--------------------|
| <b>Op. Revenue</b>  | <b>EBITDA</b>      | <b>EBIT</b>        |
| <b>329.3 (-14%)</b> | <b>69.9 (-28%)</b> | <b>56.5 (-34%)</b> |
| <b>Net profit</b>   | <b>Capex</b>       | <b>Net debt</b>    |
| <b>44.3 (-33%)</b>  | <b>18.7 (+3%)</b>  | <b>74.7</b>        |


**2024 operating revenue guidance:**  
Decrease by a mid-single-digit percentage vs 2023

- ✓ ROVI forecasts potential Risperidone ISM® sales of between 200 and 300 million euros globally in upcoming years
- ✓ Completion of the Buy-Back Programme launched on 26 July 2023
- ✓ ROVI signs an agreement to manufacture pre-filled syringes for a global pharmaceutical company

## Operating revenue €Mn



## Specialty pharma business €Mn



### Heparin franchise\*

37% of operating revenue

€120.7m -2%

### Other prescription-based pharmaceutical products

**Enoxaparin sales** €69.8m -6%

- ✓ Directly marketed in Germany, UK, Italy, France, Belgium, Portugal, Spain, Poland and Austria.
- ✓ Approved in 26 countries in Europe and 33 in RoW.
- ✓ Launched in 40 countries.

**Neparvis®** €25.0m +13%

**Orvatez®** €13.0m -4%

**Bemiparin sales** €47.2m +6%

- ✓ ROVI expects full year sales of Bemiparin to increase by a low-single-digit percentage in 2024 compared to 2023.

**Okedi®** €12.5m +141%

- ✓ Lead candidate Risperidone ISM®, a LAI of risperidone for schizophrenia.
- ✓ Launched in Europe in 2022 and approved in the U.S., Canada and Australia in 2024.

\* LMWH (Bemiparin and Enoxaparin biosimilar) + other heparins

## CDMO<sup>(1)</sup> business €Mn


Total  
€118.9m

-31%


<sup>(1)</sup> Contract Development and Manufacturing Organisation

To obtain further information on the alternative performance measures (APMs) and non-IFRS financial indicators used, including the definition thereof and a reconciliation between the applicable management indicators and the financial information set out in the consolidated financial statements prepared under IFRSs, please consult the information included on this subject on page 1 and Appendix 2 (pages 35-39) of the press release on the financial results for the first half of 2024. Said document is available on ROVI's website and may be accessed on the following link <https://www.rovi.es/en/shareholders-investors/financial-business-information>


## Gross profit €Mn



## SG&A expenses €Mn



## EBITDA €Mn



## R&D expenses €Mn €12.2

+13%


| Product                        | Potential Indication | Current Situation            | Key Milestones  |
|--------------------------------|----------------------|------------------------------|---|
| Okedi®<br>Risperidone, monthly | <b>Schizophrenia</b> | Approved                     | Approved in Europe and in the USA, Canada and Australia |
| Letrozole ISM®, annual         | <b>Breast Cancer</b> | Clinical development on hold | Phase I: Superior oestrogen suppression vs Femara®      |
| Letrozole LEBE, quarterly      | <b>Breast Cancer</b> | Phase I                      |   |
| Risperidone, quarterly         | <b>Schizophrenia</b> | Phase I                      |   |

Concentrated on improving posology for already approved compounds, which benefits risk / reward profile

Multiple FDA / GMP approved facilities to support the platform

To obtain further information on the alternative performance measures (APMs) and non-IFRS financial indicators used, including the definition thereof and a reconciliation between the applicable management indicators and the financial information set out in the consolidated financial statements prepared under IFRSs, please consult the information included on this subject on page 1 and Appendix 2 (pages 35-39) of the press release on the financial results for the first half of 2024. Said document is available on ROVI's website and may be accessed on the following link <https://www.rovi.es/en/shareholders/investors/financial-business-information>

## Net profit €Mn



(1) Calculated excluding R&D expenses in H1 2024 and H1 2023

## News flow

### SPECIALTY PHARMA

- ✓ Sales of enoxaparin biosimilar
- ✓ Additional new products to be launched
- ✓ Granting by the competent local authorities of the marketing authorisation of an Enoxaparin biosimilar outside Europe

### CDMO

- ✓ Evolution of Moderna's vaccine manufacturing
- ✓ Announcement of new contracts

### ISM@ Technology Platform

- ✓ Launch of Okedi® in Europe, Canada, Australia and other countries
- ✓ Marketing of Risvan® in USA
- ✓ Phase I clinical development of a three-monthly formulation of letrozole (Letrozole LEBE)
- ✓ Phase I clinical development of Risperidone for a 3-monthly injection